FIRST PRINCIPLE

First Principle is a specialist investor in global biotechnology equities, focused on value-determining events in the development of new medicines.

Biotechnology innovation is among the most consequential drivers of human progress. Value in the sector is created through discrete advances in scientific and clinical evidence. Public markets frequently misprice the probability and commercial significance of those advances, particularly among underfollowed clinical-stage companies.

Our mission is to bring greater analytical rigour to biotechnology investing.

First Principle evaluates scientific evidence against market expectations to identify material dislocations before consensus forms. We invest selectively ahead of defined catalysts, seeking returns driven by idiosyncratic outcomes rather than broad sector exposure.